Healio25d
FDA approves GSK’s pentavalent meningococcal vaccine
CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...
Benzinga.com22d
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...
FiercePharma27d
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...
FierceBiotech29d
GSK plans to move vaccine R&D group from Maryland to the Boston area
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirmed ...
Seeking Alpha23d
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
Business Insider22d
GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...